Johnson & Johnson (JNJ)

146.83
2.30 1.60
NYSE
Prev Close 149.18
Open 147.58
Day Low/High 147.45 / 147.63
52 Wk Low/High 109.16 / 157.00
Volume 124.15K
Exchange NYSE
Shares Outstanding 2632.82B
Market Cap 387.47B
P/E Ratio 25.86
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.

The Week Ahead, Markets Haven't Been Wrong, Closer to a Vaccine? Watching J&J

The Week Ahead, Markets Haven't Been Wrong, Closer to a Vaccine? Watching J&J

The equity market recovery is just as sloppy in performance as the economy itself.

The Nasdaq and Great Stock Picking Continue to Lead the Market Higher

The Nasdaq and Great Stock Picking Continue to Lead the Market Higher

If you're looking for some corrective action to gain momentum, then you will have to wait for broader selling.

Iconic Johnson & Johnson Is Poised for an Upside Breakout

Iconic Johnson & Johnson Is Poised for an Upside Breakout

Here's how we would trade the blue chip stock.

Emergent BioSolutions Could See Further Upside Gains

Emergent BioSolutions Could See Further Upside Gains

Most of the indicators are still bullish in this name, although some profit-taking may be occurring.

Jim Cramer: Betting Against Science Is a Mug's Game

Jim Cramer: Betting Against Science Is a Mug's Game

The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.

Jim Cramer: This Is Where to Put Your Cash as Covid Surges

Jim Cramer: This Is Where to Put Your Cash as Covid Surges

Instead of scratching your head and saying the market defies logic, look to the Cramer Covid-19 Index.

Big Tech's Big Night, Eyeing Amazon, My Kodak Moment, Powell's Blunt Assessment

Big Tech's Big Night, Eyeing Amazon, My Kodak Moment, Powell's Blunt Assessment

The Fed has done a lot, and is willing to do even more, but for now, is watching Congress. The fiscal side is where the next shoe falls.

Jim Cramer: I'm Sick of Hearing All This Nonsense About the Fed

Jim Cramer: I'm Sick of Hearing All This Nonsense About the Fed

Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Jim Cramer: Non-Traditional Banks Are Starting to Pull Away From the ETFs

Jim Cramer: Non-Traditional Banks Are Starting to Pull Away From the ETFs

Overall, the banks failed you again. But the future for two of them is much brighter than the past.

Take a Dare and Fly With This Dividend Stock

Take a Dare and Fly With This Dividend Stock

Eagle Financial is small bank name that goes under the radar of most investors, but it offers a 4% yield and boasts 34 years of increases.

Jim Cramer: 'Excuse Selling'

Jim Cramer: 'Excuse Selling'

Let's go over five excuses so you know and are armed with them when they are used and make you faint and weak-handed.

Jim Cramer: An Analyst's Dream

Jim Cramer: An Analyst's Dream

All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.

Johnson & Johnson Is Poised (Again) for an Upside Breakout

Johnson & Johnson Is Poised (Again) for an Upside Breakout

In this market, winning stocks 'stick out like a sore thumb.'

Jim Cramer: Here's My Sore Thumb Index

Jim Cramer: Here's My Sore Thumb Index

This is how you can tell which camp is winning and which is losing in this time of Covid-contradiction.

Where Health Meets Tech: 7 Testing and Diagnostics Stocks to Know

Where Health Meets Tech: 7 Testing and Diagnostics Stocks to Know

Experts pick their favorite long-term investments in medical diagnostics, testing and laboratory services.

Novavax and Its $1.6 Billion Award Just Got My Attention

Novavax and Its $1.6 Billion Award Just Got My Attention

The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.

Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers

Q2 Earnings Expectations, Phase 3 Vaccine Clinical Trials, Unemployment Numbers

What if the market is simply pricing in a quarter that had already been priced out?

7 Drug Stocks With the Right Medicine for Investors

7 Drug Stocks With the Right Medicine for Investors

These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.

I Wouldn't Buy Pfizer Shares on This Pop

I Wouldn't Buy Pfizer Shares on This Pop

I would wait until the next down day, and there will be one.

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

That's the really good news about why we could bounce back so quickly from Thursday's debacle.

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.

Jim Cramer: What's Normalcy in This Country?

Jim Cramer: What's Normalcy in This Country?

We're cheering what may be an aberration, a bullish employment number. We'll take what it brings - a wholesale shift in what we're buying and what we're selling to fund it.

Jim Cramer: This Is a Brave New Economy We're In

Jim Cramer: This Is a Brave New Economy We're In

The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.